Cyril Seroussi

BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study

Tim Heise, Grégory Meiffren, Bertrand Alluis et al. · Diabetes Obesity and Metabolism · 2018 · 42 citations

Medicine, Pharmacokinetics, Pharmacology +17

Ultra‐rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14‐day crossover treatment study in people with type 1 diabetes

Grit Andersen, Grégory Meiffren, Daniela Lamers et al. · Diabetes Obesity and Metabolism · 2018 · 37 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes

Grit Andersen, Grégory Meiffren, Susanne Famulla et al. · Diabetes Obesity and Metabolism · 2020 · 27 citations · Full text

Medicine, Endocrinology, Pharmacology +16

The Ultra-rapid Insulin (URI) BioChaperone Lispro (BCLIS) Shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs. Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII)

Bruce W. Bode, Oliver Klein, Cyril Seroussi et al. · Diabetes · 2018 · 12 citations

Medicine, Pharmacokinetics, Pharmacology +17

A co‐formulation of pramlintide and insulin <scp>A21G</scp> ( <scp>ADO09</scp> ) improves postprandial glucose and short‐term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes

Grit Andersen, Rosy Eloy, Susanne Famulla et al. · Diabetes Obesity and Metabolism · 2023 · 10 citations

Medicine, Pharmacokinetics, Pharmacology +17